Financial reports
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
11 May 21
10-K
2020 FY
Annual report
16 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
16 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
1 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
Current reports
8-K
Termination of a Material Definitive Agreement
30 Aug 21
8-K
Submission of Matters to a Vote of Security Holders
26 Aug 21
8-K
Other Events
2 Aug 21
8-K
Entry into a Material Definitive Agreement
1 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 21
8-K
Form of Support Agreement
16 Jun 21
8-K
Other Events
2 Jun 21
8-K
Kindred Biosciences Announces First Quarter 2021 Financial Results
11 May 21
8-K
Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study
20 Apr 21
8-K
Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results
16 Mar 21
Registration and prospectus
15-12B
Securities registration termination
7 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Aug 21
POS AM
Prospectus update (post-effective amendment)
30 Aug 21
25-NSE
Exchange delisting
27 Aug 21
424B5
Prospectus supplement for primary offering
3 Feb 21
S-3
Shelf registration
15 Jan 21
Proxies
DFAN14A
Additional proxy materials by non-management
10 Aug 21
DFAN14A
Additional proxy materials by non-management
9 Aug 21
DFAN14A
Additional proxy materials by non-management
2 Aug 21
DEFA14A
Additional proxy soliciting materials
2 Aug 21
DEFM14A
Proxy related to merger
21 Jul 21
PREM14A
Preliminary proxy related to merger
9 Jul 21
DFAN14A
Additional proxy materials by non-management
1 Jul 21
DFAN14A
Additional proxy materials by non-management
17 Jun 21
DEFA14A
Additional proxy soliciting materials
17 Jun 21
DFAN14A
Additional proxy materials by non-management
16 Jun 21
Other
EFFECT
Notice of effectiveness
2 Sep 21
EFFECT
Notice of effectiveness
3 Feb 21
CORRESP
Correspondence with SEC
28 Jan 21
UPLOAD
Letter from SEC
22 Jan 21
CT ORDER
Confidential treatment order
13 Sep 18
CT ORDER
Confidential treatment order
6 Jun 18
EFFECT
Notice of effectiveness
7 Feb 18
CORRESP
Correspondence with SEC
5 Feb 18
CT ORDER
Confidential treatment order
8 Dec 17
CT ORDER
Confidential treatment order
17 Jul 17
Ownership
SC 13G/A
AMERIPRISE FINANCIAL INC
14 Feb 22
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
SC 13G/A
Park West Asset Management LLC
13 Sep 21
4
Change in insider ownership
13 Sep 21
SC 13D/A
GAMCO INVESTORS, INC. ET AL
31 Aug 21
4
Richard Chin
30 Aug 21
4
Wendy Wee
30 Aug 21
4
Denise Bevers
30 Aug 21
4
Hangjun Zhan
30 Aug 21
4
Ervin Veszpremi
30 Aug 21